Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery

Objective: Patients with stage III and high-risk stage II colorectal cancer (CRC) are advised to initiate adjuvant treatment as soon as feasible and certainly before 8 to 12 weeks after resection of the tumor. A protective ileostomy is often constructed during surgery to protect a primary anastomosi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of drug assessment (London, U.K.) U.K.), 2018-01, Vol.7 (1), p.28-33
Hauptverfasser:	Cuyle, Pieter-Jan, Engelen, Anke, Moons, Veerle, Tollens, Tim, Carton, Saskia
Format:	Artikel
Sprache:	eng
Schlagworte:	colorectal cancer high-output stoma ileostomy lanreotide Original Somatostatin analogs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!